Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants

Five DNA vaccine candidates based on different SARS-CoV-2 strains.

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses | Psychedelic Invest

– Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – – Featured key opinion leaders

December 1, 2023

High-dose psilocybin shows promise for depression treatment

Researchers compare the effectiveness and acceptability of oral monotherapy with psychedelics for the treatment of depressive symptoms.

August 27, 2024

Cannabis Stocks Slide Again in May

As we described in a previous article, the Global Cannabis Stock Index fell sharply in March, plunging 15.2%, leaving it down 12.5% in the first quarter of

June 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.